BR112018016755A2 - vacina contra o vírus da zica - Google Patents
vacina contra o vírus da zicaInfo
- Publication number
- BR112018016755A2 BR112018016755A2 BR112018016755A BR112018016755A BR112018016755A2 BR 112018016755 A2 BR112018016755 A2 BR 112018016755A2 BR 112018016755 A BR112018016755 A BR 112018016755A BR 112018016755 A BR112018016755 A BR 112018016755A BR 112018016755 A2 BR112018016755 A2 BR 112018016755A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- polypeptides
- artificial nucleic
- relates
- vaccines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
a presente invenção refere-se a um ácido nucleico artificial e a polipeptídeos adequados para uso no tratamento ou profilaxia de uma infecção com o vírus da zica ou um transtorno relacionado a tal infecção. em particular, a presente invenção se refere a uma vacina contra o vírus da zica. a presente invenção é dirigida a um ácido nucleico artificial, polipeptídeos, composições e vacinas que compreendem o ácido nucleico artificial ou os polipeptídeos. a invenção se refere ainda a um método para tratar ou prevenir um transtorno ou uma doença, primeiro e segundo usos médicos do ácido nucleico artificial, polipeptídeos, composições e vacinas. além disso, a invenção se refere a um kit, particularmente a um kit de partes, que compreende o ácido nucleico artificial, polipeptídeos, composições e vacinas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2016053398 | 2016-02-17 | ||
PCT/EP2017/053721 WO2017140905A1 (en) | 2016-02-17 | 2017-02-17 | Zika virus vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018016755A2 true BR112018016755A2 (pt) | 2018-12-26 |
Family
ID=55398295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018016755A BR112018016755A2 (pt) | 2016-02-17 | 2017-02-17 | vacina contra o vírus da zica |
Country Status (6)
Country | Link |
---|---|
US (2) | US11723967B2 (pt) |
EP (1) | EP3416683A1 (pt) |
BR (1) | BR112018016755A2 (pt) |
MX (2) | MX2018009917A (pt) |
SG (2) | SG11201806340YA (pt) |
WO (1) | WO2017140905A1 (pt) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109045289A (zh) | 2013-02-22 | 2018-12-21 | 库瑞瓦格股份公司 | 疫苗接种和抑制pd-1途径的组合 |
JP6896421B2 (ja) | 2013-08-21 | 2021-06-30 | キュアバック アーゲー | 呼吸器合胞体ウイルス(rsv)ワクチン |
SI3766916T1 (sl) | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc. | Formulacije novih lipidov in lipidnih nanodelcev za dostavo nukleinskih kislin |
DE202015010000U1 (de) | 2014-12-12 | 2023-07-03 | CureVac SE | Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression |
EP3294885B1 (en) | 2015-05-08 | 2020-07-01 | CureVac Real Estate GmbH | Method for producing rna |
EP3744843A1 (en) | 2015-05-29 | 2020-12-02 | CureVac Real Estate GmbH | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
WO2017004143A1 (en) | 2015-06-29 | 2017-01-05 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
ES2937963T3 (es) * | 2015-07-21 | 2023-04-03 | Modernatx Inc | Vacunas de enfermedad infecciosa |
EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
CN113636947A (zh) | 2015-10-28 | 2021-11-12 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
SG11201806340YA (en) | 2016-02-17 | 2018-09-27 | Curevac Ag | Zika virus vaccine |
CN115927399A (zh) * | 2016-02-25 | 2023-04-07 | 宾夕法尼亚大学理事会 | 新抗寨卡病毒疫苗 |
US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
EP3448427A1 (en) | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
WO2017191264A1 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Nucleic acid molecules and uses thereof |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
WO2017212009A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
EP3468593A4 (en) * | 2016-06-09 | 2019-12-18 | Beth Israel Deaconess Medical Center, Inc. | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING A ZIKA VIRUS INFECTION |
WO2018029452A1 (en) * | 2016-08-08 | 2018-02-15 | The Secretary Of State For Health | Flavivirus diagnostic assay |
WO2018053451A1 (en) | 2016-09-16 | 2018-03-22 | Pebble Labs | Novel paratransgenic system for the biocontrol of disease-transmitting mosquitos |
US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
JP2020503279A (ja) * | 2016-12-01 | 2020-01-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | ジカウイルス感染用の血清学的アッセイ |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
CN110582304A (zh) | 2016-12-08 | 2019-12-17 | 库尔维科公司 | 用于治疗或预防肝脏疾病的rna |
WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
JP2020513824A (ja) | 2017-03-24 | 2020-05-21 | キュアバック アーゲー | Crispr関連タンパク質をコードする核酸、及びその使用 |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
AU2018256867A1 (en) | 2017-04-27 | 2019-11-14 | The Johns Hopkins University | Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus |
CN110799492B (zh) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
EP3668833A1 (en) | 2017-08-16 | 2020-06-24 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
SG11202002044WA (en) * | 2017-09-21 | 2020-04-29 | Emergex Vaccines Holding Ltd | MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus |
MX2020003995A (es) | 2017-10-19 | 2020-07-22 | Curevac Ag | Nuevas moleculas de acido nucleico artificiales. |
US11730802B2 (en) * | 2017-11-03 | 2023-08-22 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
US11692002B2 (en) | 2017-11-08 | 2023-07-04 | CureVac SE | RNA sequence adaptation |
SG11202004234SA (en) * | 2017-11-09 | 2020-06-29 | Pasteur Institut | A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition |
US11739348B2 (en) | 2017-11-10 | 2023-08-29 | The Research Institute At Nationwide Children's Hospital | Recombinant vectors encoding Zika virus protein subunits |
US11931406B2 (en) | 2017-12-13 | 2024-03-19 | CureVac SE | Flavivirus vaccine |
WO2019122380A1 (en) * | 2017-12-21 | 2019-06-27 | PEPperPRINT GmbH | NS2b AS MARKER FOR ZIKA VIRUS INFECTIONS |
SG11202005760PA (en) | 2017-12-21 | 2020-07-29 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
CN108210921A (zh) * | 2017-12-29 | 2018-06-29 | 广州恩宝生物医药科技有限公司 | 一种寨卡病毒疫苗及其制备方法 |
JP2021509400A (ja) | 2018-01-06 | 2021-03-25 | イマージェクス ヴァクシンズ ホールディング リミテッドEmergex Vaccines Holding Limited | 複数のフラビウイルスの予防および治療を目的としたmhcクラスi関連ペプチド |
CN108484737B (zh) * | 2018-02-09 | 2021-04-23 | 四川农业大学 | 坦布苏病毒非结构蛋白ns4b截短蛋白的表达方法及其产品和应用 |
BR112020019719A2 (pt) * | 2018-03-29 | 2021-01-26 | Emergex Vaccines Holding Limited | composições de vacina |
AU2019310347A1 (en) | 2018-07-23 | 2021-03-04 | The University Of Adelaide | Zika virus vaccine |
WO2020041309A1 (en) * | 2018-08-21 | 2020-02-27 | The Regents Of The University Of Michigan | Materials and methods for inhibiting flavivirus infection |
CN114901360A (zh) | 2019-12-20 | 2022-08-12 | 库瑞瓦格股份公司 | 用于递送核酸的新型脂质纳米颗粒 |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US20230065376A1 (en) * | 2020-02-05 | 2023-03-02 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
EP4114844A4 (en) * | 2020-03-03 | 2024-04-10 | Mayo Found Medical Education & Res | ZIKA VIRUS POLYPEPTIDES |
CN111514286B (zh) * | 2020-04-01 | 2022-03-08 | 中国科学院过程工程研究所 | 一种寨卡病毒e蛋白结合疫苗及其制备方法 |
AU2021405281A1 (en) | 2020-12-22 | 2023-07-06 | CureVac SE | Rna vaccine against sars-cov-2 variants |
CU20210063A7 (es) * | 2021-07-28 | 2023-03-07 | Ct Ingenieria Genetica Biotecnologia | Antígeno recombinante para la inducción de respuesta inmune contra el virus zika |
WO2023018817A1 (en) | 2021-08-11 | 2023-02-16 | Sanofi Pasteur Inc. | Truncated influenza neuraminidase and methods of using the same |
IL309505A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Lipid nanoparticles for nucleic acid delivery |
IL309502A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2340532T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo. |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
CA2710534C (en) | 2008-01-31 | 2018-09-04 | Curevac Gmbh | Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
US8691961B1 (en) * | 2009-11-09 | 2014-04-08 | Integral Molecular, Inc. | Flavivirus reporter virus and methods of making and using the same |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
ES2660459T3 (es) | 2012-03-27 | 2018-03-22 | Curevac Ag | Moléculas de ácido nucleico artificiales |
AU2013242404B2 (en) | 2012-03-27 | 2018-08-30 | CureVac SE | Artificial nucleic acid molecules for improved protein or peptide expression |
CN104321432B (zh) | 2012-03-27 | 2018-08-10 | 库瑞瓦格股份公司 | 包含5′top utr的人工核酸分子 |
US20150306249A1 (en) | 2012-05-25 | 2015-10-29 | Curevac Gmbh | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
CN109045289A (zh) | 2013-02-22 | 2018-12-21 | 库瑞瓦格股份公司 | 疫苗接种和抑制pd-1途径的组合 |
WO2015024667A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Method for increasing expression of rna-encoded proteins |
SG11201510748PA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Composition and vaccine for treating lung cancer |
JP6896421B2 (ja) | 2013-08-21 | 2021-06-30 | キュアバック アーゲー | 呼吸器合胞体ウイルス(rsv)ワクチン |
CA2915712A1 (en) | 2013-08-21 | 2015-02-26 | Margit SCHNEE | Rabies vaccine |
CA2915730A1 (en) | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
RU2016109938A (ru) | 2013-08-21 | 2017-09-26 | Куревак Аг | Композиция и вакцина для лечения рака предстательной железы |
ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
AU2014375404C1 (en) | 2013-12-30 | 2020-11-19 | CureVac Manufacturing GmbH | Methods for RNA analysis |
SG11201603144QA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Artificial nucleic acid molecules |
CA2935878C (en) | 2014-03-12 | 2023-05-02 | Curevac Ag | Combination of vaccination and ox40 agonists |
CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
MX2016016170A (es) | 2014-06-10 | 2017-03-28 | Curevac Ag | Metodos y medios para aumentar la produccion de arn. |
DE202015010000U1 (de) | 2014-12-12 | 2023-07-03 | CureVac SE | Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression |
EP3233113A1 (en) | 2014-12-16 | 2017-10-25 | CureVac AG | Ebolavirus and marburgvirus vaccines |
AU2015373404B2 (en) | 2014-12-30 | 2021-09-09 | CureVac SE | Artificial nucleic acid molecules |
WO2016165825A1 (en) | 2015-04-13 | 2016-10-20 | Curevac Ag | Method for producing rna compositions |
WO2016165831A1 (en) | 2015-04-17 | 2016-10-20 | Curevac Ag | Lyophilization of rna |
JP6912384B2 (ja) | 2015-04-22 | 2021-08-04 | キュアバック アーゲー | 癌疾患の処置のための、rna含有組成物 |
SG11201708867UA (en) | 2015-04-30 | 2017-11-29 | Curevac Ag | Immobilized poly(n)polymerase |
SG11201708681SA (en) | 2015-04-30 | 2017-11-29 | Curevac Ag | Method for in vitro transcription using an immobilized restriction enzyme |
EP3294885B1 (en) | 2015-05-08 | 2020-07-01 | CureVac Real Estate GmbH | Method for producing rna |
US11559570B2 (en) | 2015-05-15 | 2023-01-24 | CureVac SE | Prime-boost regimens involving administration of at least one mRNA construct |
EP3297682B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
WO2016184575A1 (en) | 2015-05-20 | 2016-11-24 | Curevac Ag | Dry powder composition comprising long-chain rna |
EP3744843A1 (en) | 2015-05-29 | 2020-12-02 | CureVac Real Estate GmbH | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
EP4098743A1 (en) | 2015-05-29 | 2022-12-07 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
WO2016203025A1 (en) | 2015-06-17 | 2016-12-22 | Curevac Ag | Vaccine composition |
US10799575B2 (en) | 2015-06-25 | 2020-10-13 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (VLPS) |
EP4239080A3 (en) | 2015-07-01 | 2023-11-01 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
ES2937963T3 (es) * | 2015-07-21 | 2023-04-03 | Modernatx Inc | Vacunas de enfermedad infecciosa |
US20200085852A1 (en) | 2015-08-05 | 2020-03-19 | Curevac Ag | Epidermal mrna vaccine |
EP3332019B1 (en) | 2015-08-07 | 2019-12-18 | CureVac AG | Process for the in vivo production of rna in a host cell |
CN108138187B (zh) | 2015-08-10 | 2022-07-19 | 库瑞瓦格房地产有限公司 | 增加环状dna分子复制的方法 |
CN108026537B (zh) | 2015-08-28 | 2022-02-08 | 库瑞瓦格股份公司 | 人工核酸分子 |
EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
WO2017070624A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
US20180312545A1 (en) | 2015-11-09 | 2018-11-01 | Curevac Ag | Optimized nucleic acid molecules |
WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
WO2017108087A1 (en) | 2015-12-21 | 2017-06-29 | Curevac Ag | Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay |
EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
EP3414340B1 (en) | 2016-02-12 | 2023-08-09 | CureVac SE | Method for analyzing rna |
EP3417069A1 (en) | 2016-02-15 | 2018-12-26 | CureVac AG | Method for analyzing by-products of rna in vitro transcription |
SG11201806340YA (en) | 2016-02-17 | 2018-09-27 | Curevac Ag | Zika virus vaccine |
US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
WO2017161151A1 (en) * | 2016-03-16 | 2017-09-21 | Novavax, Inc. | Vaccine compositions containing modified zika virus antigens |
WO2017162297A1 (en) | 2016-03-24 | 2017-09-28 | Curevac Ag | Immobilized inorganic pyrophosphatase (ppase) |
EP3445392A1 (en) | 2016-04-22 | 2019-02-27 | CureVac AG | Rna encoding a tumor antigen |
EP3448427A1 (en) | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
EP3452086A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Influenza mrna vaccines |
US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
WO2017191264A1 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Nucleic acid molecules and uses thereof |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
EP3464619A1 (en) | 2016-05-25 | 2019-04-10 | CureVac AG | Novel biomarkers |
EP3468609A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Cationic carriers for nucleic acid delivery |
WO2017212009A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
US20190381180A1 (en) | 2016-06-09 | 2019-12-19 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
US20190336611A1 (en) | 2016-06-09 | 2019-11-07 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
SG10201913631TA (en) | 2016-08-19 | 2020-03-30 | Curevac Ag | Rna for cancer therapy |
WO2018052549A1 (en) * | 2016-09-19 | 2018-03-22 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Zika virus vaccines |
BR112019008481A2 (pt) | 2016-10-26 | 2020-03-03 | Curevac Ag | Vacinas de mrna de nanopartículas lipídicas |
US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
CN110582304A (zh) | 2016-12-08 | 2019-12-17 | 库尔维科公司 | 用于治疗或预防肝脏疾病的rna |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
US11241490B2 (en) | 2017-01-11 | 2022-02-08 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified RNA for inducing an immune response against zika virus |
EP3595715A1 (en) | 2017-03-17 | 2020-01-22 | CureVac AG | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
JP2020513824A (ja) | 2017-03-24 | 2020-05-21 | キュアバック アーゲー | Crispr関連タンパク質をコードする核酸、及びその使用 |
BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
US11931406B2 (en) | 2017-12-13 | 2024-03-19 | CureVac SE | Flavivirus vaccine |
SG11202005760PA (en) | 2017-12-21 | 2020-07-29 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
EP3773702A2 (en) | 2018-04-05 | 2021-02-17 | CureVac AG | Novel yellow fever nucleic acid molecules for vaccination |
SG11202008225PA (en) | 2018-04-17 | 2020-11-27 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
MX2020013148A (es) | 2018-06-28 | 2021-03-02 | CureVac RNA Printer GmbH | Biorreactor para la transcripcion in vitro de arn. |
SG11202106666UA (en) | 2018-12-21 | 2021-07-29 | Curevac Ag | Methods for rna analysis |
CN113453707A (zh) | 2018-12-21 | 2021-09-28 | 库瑞瓦格股份公司 | 用于疟疾疫苗的rna |
CA3164395A1 (en) | 2020-01-11 | 2021-07-15 | Lyndsey M. LINKE | A microbial system for production and delivery of eukaryote-translatable mrna to eukarya |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
WO2021211343A1 (en) | 2020-04-13 | 2021-10-21 | Modernatx, Inc. | Zika virus mrna vaccines |
-
2017
- 2017-02-17 SG SG11201806340YA patent/SG11201806340YA/en unknown
- 2017-02-17 EP EP17706710.5A patent/EP3416683A1/en active Pending
- 2017-02-17 MX MX2018009917A patent/MX2018009917A/es unknown
- 2017-02-17 SG SG10201913630YA patent/SG10201913630YA/en unknown
- 2017-02-17 BR BR112018016755A patent/BR112018016755A2/pt unknown
- 2017-02-17 WO PCT/EP2017/053721 patent/WO2017140905A1/en active Application Filing
- 2017-02-17 US US15/999,469 patent/US11723967B2/en active Active
-
2018
- 2018-08-15 MX MX2018014573A patent/MX2018014573A/es unknown
-
2023
- 2023-06-21 US US18/338,612 patent/US20240024453A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2018014573A (es) | 2019-09-04 |
EP3416683A1 (en) | 2018-12-26 |
SG11201806340YA (en) | 2018-09-27 |
SG10201913630YA (en) | 2020-03-30 |
US11723967B2 (en) | 2023-08-15 |
WO2017140905A1 (en) | 2017-08-24 |
US20210205434A1 (en) | 2021-07-08 |
US20240024453A1 (en) | 2024-01-25 |
MX2018009917A (es) | 2019-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018016755A2 (pt) | vacina contra o vírus da zica | |
BR112019000598A2 (pt) | rna para terapia de câncer | |
BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
WO2018115507A3 (en) | Henipavirus vaccine | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
CL2019003264A1 (es) | Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151) | |
BR112018000862A2 (pt) | composições de vacina | |
BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
CL2018001159A1 (es) | Vacuna para adenovirus aviar (divisional de solicitud n° 358-2016) | |
BR112012020839A2 (pt) | vacinas para uso na profilaxe e tratamento de doença de vírus da influenza | |
BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
BR112013009649A2 (pt) | composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição | |
BR112018068342A2 (pt) | vacina de vírus zika vivo atenuado | |
PE20151588A1 (es) | Vacuna contra el virus del dengue | |
BR112020016454A8 (pt) | Tratamento utilizando rna que codifica citocina | |
BR112017015789A2 (pt) | vacina de vírus da influenza suína bivalente | |
BR112022005687A2 (pt) | Vacinas contra o hbv e métodos para tratar o hbv | |
BR112017028212A2 (pt) | vacinação concomitante contra dengue e febre amarela | |
BR112017017346A2 (pt) | implantes para esculpir, aumentar ou corrigir atributos faciais tais como o queixo | |
BR112017002440A2 (pt) | vírus da diarreia epizoótica porcina mutante para utilização em uma vacina | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
BR112016006210A2 (pt) | terapia e vacina contra gripe | |
BR112016030294A8 (pt) | cepa de bactérias probióticas de lactobacillus e uma vacina de aves domésticas, composição, ovo de aves domésticas embrionado, kit, e, método de vacinação in ovo de aves domésticas | |
BR112015031226A2 (pt) | Composição de vacina, e, uso da composição de vacina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |